Status: Recruiting
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Participants needed: 40
Trial details
Phase: Phase 2Age: 1-17Biological sex: AllType: InterventionalSponsor: Spectrum Pharmaceuticals, IncUpdated: Jun 24, 2026Locations: 5
Eligibility criteria
Participant must have a pathologic/histologic confirmed newly diagnosed/relapsed... [+5]
Participant has an uncontrollable infection, has an underlying medical condition... [+8]